A serendipitous discovery was that ceritinib also displayed anti-proliferative activity in vitro against ALK-negative lung cancer cell lines [23] and demonstrated prominent anti-tumor activity in non-small cell lung cancer patients without ALK rearrangement in clinical trials [38], indicating a broader mechanism beyond ALK inhibition. This evidence concerns the gene ALK and lung carcinoma.